nice glp 1 guidelines weight loss How should GLP-1 receptor agonists be managed in the perioperative period? New oral GLP-1 drug delivers

Regeneron has signaled plans to initiate Phase 3 trials, likely in 2027, using its own in-licensed GLP-1/GIP dual agonist (olatorepatide) as the incretin backbone rather than Novo Nordisks semaglutide

As of May 2026, FDA has also proposed excluding compounded semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period closing June 29, 2026

In streptozotocin-induced T1DM Swiss TO mice, liraglutide improved mechanical properties in bone tissue, but failed to reverse cortical microstructure degradation or improve whole bone mechanical properties (18)

Semaglutide activates GLP-1 receptors exclusively

Moreover, cardiometabolic effects of GLP-1 are attenuated in obesity and T2D, via mechanisms that may involve impaired p38-MAPK signaling